Non-A non-B hepatitis after transfusion of factor VIII in infrequently treated patients.

Abstract

Thirty patients who had not previously received treatment with factor VIII concentrate or who had been treated only infrequently with factor VIII concentrate were studied after a transfusion of factor VIII. Tests of liver function were performed frequently. Four patients had evidence of chronic liver disease before transfusion. In 17 of the remaining 26 patients serum transaminase activities became raised and 10 patients developed jaundice. All of the nine patients who had not previously received factor VIII transfusion developed non-A non-B hepatitis. Four out of 10 patients followed up for a year had persisting abnormalities of liver function.The pattern of illness suggests that more than one serotype of non-A non-B hepatitis virus may be transmitted by factor VIII concentrate prepared by the National Health Service from volunteer donors in the United Kingdom.

A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus

“…The duration of HCV infection was calculated assuming that the first infusion with blood, plasma, or non-virusinactivated concentrates had transmitted HCV. 9,10 At enrollment, all patients underwent a full clinical examination and routine liver chemistries. Patients were also tested for serum markers of HBV and HCV (hepatitis B surface antigen and anti-HCV, second-generation enzyme-linked immunosorbent assay [ELISA]; Ortho Diagnostics, Raritan, NJ), anti-HIV (ELISA; Ortho Diagnostics), HBV-DNA (HBV bDNA; Bayer, Tarrytown, NY), HCV genotype (Inno-LIPa; Innogenetics, Ghent, Belgium), and AFP (ELISA; Abbott Laboratories, Chicago, IL).…”

Hemophilia treatment in historical perspective: a review of medical and social developments

“…The large majority of hemophilia patients has also been infected with non-A non-B hepatitis [43,47]. The number of infected patients, äs well äs the percentage of patients demonstrating elevated liver enzymes, may be somewhat lower in those treated with cryoprecipitate than in those treated with large pool concentrates [127].…”

Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort study

“…[1][2][3][4] Once infected, about 80% of patients develop chronic hepatitis C. 5 After 20 years of infection, 10% of patients progress to cirrhosis and an additional 10% to end-stage liver disease (ESLD; ie, liver failure, hepatocellular carcinoma, liver-related death). 6 HIV coinfection, alcohol abuse, older age at infection, and male sex are the main determinants associated with faster progression of liver disease.…”